Journal Information
Vol. 44. Issue S1.
Pages S32 (October 2022)
Share
Share
Download PDF
More article options
Vol. 44. Issue S1.
Pages S32 (October 2022)
PP 11
Open Access
THE DIVERSITY OF PRESENTATION AND MANAGEMENT OF SUBCUTANEOUS PANNICULITIS –LIKE T-CELL LYMPHOMA WITH ASSOCIATED HEMOPHAGOCYTIC SYNDROME - CASE SERIES ANALYSIS
Visits
528
Agnieszka Giza1, Justyna Jedras1, Maria Rozploch2, Ewa Czepko3, Marcin Jonca4, Dagmara Zimowska-Curylo1, Mateusz Wilk1, Malgorzata Razny4, Walentyna Balwierz3, Tomasz Sacha1
1 Department of Hematology, Jagiellonian University Medical College, Krakow, Poland
2 Student Scientific Group, Department of Dermatology, Jagiellonian University Medical College, Krakow, Poland
3 University Children's Hospital, Department of Pediatric Oncology and Hematology, Krakow, Poland
4 Rydygier's Specialistic Hospital, Department of Hematology, Krakow, Poland
This item has received

Under a Creative Commons license
Article information
Special issue
This article is part of special issue:
Vol. 44. Issue S1
More info
Objective

Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare hematological malignancy affecting subcutaneous adipose tissue, typically with no involvement of the lymph nodes. SPTCL is associated with the increased risk of the hemophagocytic syndrome (HPS), significantly affecting prognosis and overall survival. This study aimed to present different clinical characteristics, management strategies, and outcomes in three patients diagnosed with SPTCL.

Methodology

A retrospective study of the three patients diagnosed with SPTCL admitted to Hematology Departments in Krakow was conducted. Collected data included patients’ clinical characteristics and symptoms, laboratory testing, imaging tests, implemented treatment strategies and response assessment.

Results

The analyzed patients (aged 15-35), presented lesions involving mainly skin in 2 patients, and mesenterium in one subject; HPS was confirmed in each case. The first line treatment consisted of HLH protocols followed by next line chemotherapies in two patients, and then with high dose therapy in one case. Cyclosporine A (CyA) was implemented in two patients, and in one case this was an initial choice. CR was achieved in 2 patients, including the subject treated with CyA from the beginning.

Conclusion

This series shows a diversity of presentations and implemented management in three patients. Since SPTCL is an extremely rare condition with no standardized established therapy, choosing the optimal treatment approach is a relevant problem. The increasing data shows the effectiveness and safety of immunosuppressive treatment with CyA versus intensive chemotherapy and supports the application of CyA also in patients with developed HPS.

Full text is only aviable in PDF
Idiomas
Hematology, Transfusion and Cell Therapy
Article options
Tools